Advertisement

Bone Biomarkers in Gestational Hypertension

  • Despina D. Briana
  • Ariadne Malamitsi-PuchnerEmail author
Reference work entry
  • 840 Downloads
Part of the Biomarkers in Disease: Methods, Discoveries and Applications book series (BDMDA)

Abstract

The skeletal system undergoes a continuous process of remodeling throughout life, which involves a delicate balance between bone resorption due to osteoclastic activation and new bone formation due to osteoblastic activity. Biochemical markers of bone turnover are reliable indices for measuring changes of bone formation and resorption, reflecting the dynamics of bone metabolism at the cellular level. During normal pregnancy, major changes occur in maternal calcium homeostasis and bone metabolism, in order to fulfill the calcium demand of the fetus for skeletal growth and mineralization. Fetal calcium requirements can be met by calcium mobilization from the maternal skeleton through hormone-mediated adjustment of maternal calcium metabolism. Due to limitations in the application of bone densitometry during pregnancy, biochemical markers are effective alternatives to estimate bone turnover. The diphasic changes in maternal bone histology (temporary loss of cancellous bone in early pregnancy restored by term gestation) are consistent with corresponding blood biochemistry changes: increased bone resorption markers in the first trimester, followed by elevated bone formation markers at term. Maternal bone turnover during pregnancy is reportedly enhanced in hypertensive disorders of pregnancy, including preeclampsia (PE) and pregnancy-induced hypertension (PIH), although data are not consistent. Biochemical markers provide evidence for increased maternal bone turnover in PE, probably leading to a further reduction in maternal bone mineral density (BMD). In contrast, in PIH, data are scarce and do not support considerable changes in maternal bone metabolism.

Keywords

Pregnancy Preeclampsia Pregnancy-induced hypertension Bone turnover Biochemical markers Bone mineral density 

List of Abbreviations

ALP

Alkaline phosphatase

BALP

Bone-specific alkaline phosphatase

BMD

Bone mineral density

BMI

Body mass index

DPD

Deoxypyridinoline

ICTP

Cross-linked carboxyl-terminal telopeptide of type I collagen

IL-6

Interleukin-6

NTx

N-telopeptide of type I collagen

OC

Osteocalcin

OPG

Osteoprotegerin

PE

Preeclampsia

PICP

Carboxyl-terminal pro-peptide of type I collagen

PIH

Pregnancy-induced hypertension

PTH

Parathormone

RANKL

Receptor activator of nuclear factor-kB ligand

TGF-β

Transforming growth factor-β

TNF-alpha

Tumor necrosis factor-alpha

References

  1. Anim-Nyame N, Sooranna SR, Jones J, et al. Biochemical markers of maternal bone turnover are elevated in pre-eclampsia. BJOG. 2001;108:258–62.PubMedGoogle Scholar
  2. Anim-Nyame N, Sooranna SR, Jones J, et al. A longitudinal study of biochemical markers of bone turnover during normal pregnancy and pregnancies complicated by pre-eclampsia. BJOG. 2002;109:708–13.CrossRefPubMedGoogle Scholar
  3. Bhandari V, Fall P, Raisz L, et al. Potential biochemical growth markers in premature infants. Am J Perinatol. 1999;16:339–49.CrossRefPubMedGoogle Scholar
  4. Briana DD, Gourgiotis D, Boutsikou M, et al. Perinatal bone turnover in term pregnancies: the influence of intrauterine growth restriction. Bone. 2008;42:307–13.CrossRefPubMedGoogle Scholar
  5. Briana DD, Boutsikou M, Baka S, et al. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term: the impact of intrauterine growth restriction. Neonatology. 2009;96:132–6.CrossRefPubMedGoogle Scholar
  6. Briana DD, Boutsikou M, Boutsikou T, et al. Relationships between maternal novel adipocytokines and bone biomarkers in complicated by gestational hypertensive disorders and normal pregnancies. J Matern Fetal Neonatal Med. 2013;26:1219–22.CrossRefPubMedGoogle Scholar
  7. Brown MA. The physiology of pre-eclampsia. Clin Exp Pharmacol Physiol. 1995;22:781–91.CrossRefPubMedGoogle Scholar
  8. Camozzi V, Tossi A, Simoni E, et al. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest. 2007;30 Suppl 6:13–7.PubMedGoogle Scholar
  9. Djurovic S, Schjetlein R, Wisloff F, et al. Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. Clin Genet. 1997;52:371–6.CrossRefPubMedGoogle Scholar
  10. Dorota DK, Bogdan KG, Mieczyslaw G, et al. The concentrations of markers of bone turnover in normal pregnancy and preeclampsia. Hypertens Pregnancy. 2012;31:166–76.CrossRefPubMedGoogle Scholar
  11. Eriksen EF, Charles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993;8:127–32.CrossRefPubMedGoogle Scholar
  12. Gorzelak M, Darmochwal-Kolarz D, Jablonski M, et al. The concentrations of osteocalcin and degradation products of type I collagen in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2001;98:23–7.CrossRefPubMedGoogle Scholar
  13. Graves SW, Wood RJ, Brown EM, et al. Calcium and calciotropic hormones in transient hypertension of pregnancy versus pre-eclampsia. Hypertens Pregnancy. 1994;13:87–95.CrossRefGoogle Scholar
  14. Greer IA, Lyall F, Perera T, et al. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84:937–40.PubMedGoogle Scholar
  15. Gu Y, Lewis DF, Deere K, et al. Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in woman with preeclampsia. J Immunol. 2008;181:4418–22.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hong JS, Santolaya-Forgas J, Romero R, et al. Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol. 2005;193:1011–5.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222:222–35. Fetal Mat Med Rev. 1997;9:73–101.CrossRefPubMedGoogle Scholar
  18. Khovidhunkit W, Epstein S. Osteoporosis in pregnancy. Osteoporos Int. 1996;6:345–54.CrossRefPubMedGoogle Scholar
  19. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–80.CrossRefPubMedGoogle Scholar
  20. Kumar A, Devi SG, Prasad S, et al. Bone turnover in preeclampsia-complicated pregnancy in North Indian women. J Obstet Gynaecol Res. 2012;38:172–9.CrossRefPubMedGoogle Scholar
  21. Kumtepe Y, Aksoy H, Ingec M. Bone turnover in preeclamptic and normotensive pregnancy. Int J Gynaecol Obstet. 2005;88:323–4.CrossRefPubMedGoogle Scholar
  22. Lalau JD, Jans I, el Esper N, et al. Calcium metabolism, plasma parathyroid hormone, and calcitriol in transient hypertension of pregnancy. Am J Hypertens. 1993;6(6 Pt1):522–7.CrossRefPubMedGoogle Scholar
  23. Leinbbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143:123–50.CrossRefGoogle Scholar
  24. Low MG. Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem J. 1987;244:1–13.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Magni P, Dozio E, Galliera E, et al. Molecular aspects of adipokine-bone interactions. Curr Mol Med. 2010;10:522–32.PubMedGoogle Scholar
  26. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7:134–9.CrossRefPubMedGoogle Scholar
  27. More C, Bhattoa HP, Bettembuk P, et al. The effects of pregnancy and lactation on hormonal status and biochemical markers of bone turnover. Eur J Obstet Gynecol Reprod Biol. 2003;106:209–13.CrossRefPubMedGoogle Scholar
  28. Mori M. Beta-crosslaps. Nippon Rinsho. 2004;62:247–9.PubMedGoogle Scholar
  29. Morikawa H, Chough SY, Ohara N, et al. Pregnancy induced hypertension (PIH) and osteoporosis. Nippon Naibunpi Gakkai Zasshi. 1989;65:1123–34.PubMedGoogle Scholar
  30. Mundy GR. The effects of TGF-beta on bone. Ciba Found Symp. 1991;157:137–43.PubMedGoogle Scholar
  31. Namgung R, Tsang RC. Bone in the pregnant mother and newborn at birth. Clin Chim Acta. 2003;333:1–11.CrossRefPubMedGoogle Scholar
  32. Naylor KE, Rogers A, Fraser RB, et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003;88:5361–5.CrossRefPubMedGoogle Scholar
  33. Ogueh O, Khastgir G, Abbas A, et al. The feto-placental unit stimulates the pregnancy-associated increase in maternal bone metabolism. Hum Reprod. 2000;15:1834–7.CrossRefPubMedGoogle Scholar
  34. Pitkin RM. Calcium metabolism in pregnancy and the perinatal period: a review. Am J Obstet Gynecol. 1985;151:99–109.CrossRefPubMedGoogle Scholar
  35. Puistola U, Risteli L, Kauppilla A, et al. Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J Clin Endocrinol Metab. 1993;77:178–82.PubMedGoogle Scholar
  36. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999;45:1353–8.PubMedGoogle Scholar
  37. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88:1–17.CrossRefPubMedGoogle Scholar
  38. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int. 1993;53:94–8.CrossRefGoogle Scholar
  39. Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27:1229–41.CrossRefPubMedGoogle Scholar
  40. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1998;13:297–302.CrossRefPubMedGoogle Scholar
  41. Sanchez-Ramos L, Sandroni S, Andres FJ, et al. Calcium excretion in pre-eclampsia. Obstet Gynecol. 1991;77:510–3.PubMedGoogle Scholar
  42. Shaarawy M, Zaki S, Ramzi AM, et al. Feto-maternal bone remodeling in normal pregnancy and preeclampsia. J Soc Gynecol Investig. 2005;12:343–8.CrossRefPubMedGoogle Scholar
  43. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.CrossRefPubMedGoogle Scholar
  44. Sowers M, Scholl T, Grewal J, et al. IGF-I, osteocalcin and bone change in pregnant normotensive and pre-eclamptic women. J Clin Endocrinol Metab. 2001;86:5898–903.CrossRefPubMedGoogle Scholar
  45. To WW, Wong WN. Bone mineral density changes in pregnancies with gestational hypertension: a longitudinal study using quantitative ultrasound measurements. Arch Gynecol Obstet. 2011;284:45.CrossRefGoogle Scholar
  46. To WW, Wong MW, Leung TW. Relationship between bone mineral density changes in pregnancy and maternal and pregnancy characteristics: a longitudinal study. Acta Obstet Gynecol Scand. 2003;82:820–7.CrossRefPubMedGoogle Scholar
  47. Uemura H, Yasui T, Kiyokawa M, et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol. 2002;174:353–9.CrossRefPubMedGoogle Scholar
  48. Vitoratos N, Lambrinoudaki I, Rizos D, et al. Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. Eur J Obstet Gynecol Reprod Biol. 2011;154:141–5.CrossRefPubMedGoogle Scholar
  49. Wada S, Fukawa T, Kamiya S. Biochemical markers of bone turnover. new aspect. Bone metabolic markers available in daily practice. Clin Calcium. 2009;19:1075–82.PubMedGoogle Scholar
  50. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251–63.CrossRefPubMedGoogle Scholar
  51. Wang W, Xu S, Zan Z. The relation of parathyroid function to pregnancy-induced hypertensen. Chin Med J. 1995;108:576–78.Google Scholar
  52. Wild J, Pateisky P, Kussel L, et al. Preeclampsia – a risk factor for osteoporosis? Analysis of maternal Sclerostin levels and markers of bone turnover in patients with pre-eclampsia. Hypertens Pregnancy. 2014;33:333–40.CrossRefPubMedGoogle Scholar
  53. Yamaga A, Taga M, Minaguchi H, et al. Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium: a longitudinal study. J Clin Endocrinol Metab. 1996;81:752–6.PubMedGoogle Scholar
  54. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329–37.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Department of NeonatologyAthens University Medical SchoolAthensGreece

Personalised recommendations